Earnings call transcript: NordHealth Q2 2025 sees revenue growth, stock dips

NordHealth reported Q2 2025 revenue up 5.4% to €12.9 million, driven by 13.5% recurring revenue growth, but its stock fell 2.79% due to a negative adjusted EBITDA minus CapEx of €1 million. The company is significantly increasing investments in AI development and DACH region localization, revising its full-year adjusted EBITDA minus CapEx guidance to -€4 million to -€2 million. These strategic outlays are aimed at capitalizing on anticipated large enterprise rollouts in H2 2025/2026, which could add €4.5 million in ARR, positioning NordHealth for future growth despite current profitability headwinds and competitive market dynamics.

Analysis

NordHealth's Q2 2025 results highlight a strategic pivot towards aggressive investment at the expense of near-term profitability. While revenue grew 5.4% year-over-year to €12.9 million, fueled by a robust 13.5% increase in recurring revenue, the market reacted negatively with a 2.79% stock decline. This was driven by a negative adjusted EBITDA minus CapEx of €1 million and a significant downward revision of the full-year guidance for this metric to a range of -€4 million to -€2 million. Management attributes this burn to accelerated investments in two key areas: developing a suite of AI features to create a strong competitive moat and localizing its platform for the large DACH market. The strategy is underpinned by major upcoming enterprise rollouts with clients like AmeriVet, which are expected to add €4.5 million in annual recurring revenue in H2 2025 and 2026. Despite the negative cash flow, the company maintains a strong financial position with €20.5 million in cash, no interest-bearing debt, and a high Altman Z-Score of 11.18, providing a buffer to execute its growth initiatives.

Key Decisions for Investors

• Investors should view NordHealth as a long-term growth investment, weighing the current pressure on profitability against the potential for significant market share capture through its strategic AI and DACH expansion initiatives.
• Closely monitor the progress of the large enterprise rollouts (AmeriVet, Vets for Pets) in H2 2025 and 2026, as the successful implementation of the projected €4.5 million in new ARR is the primary validation for the current high-investment strategy.
• Track the company's cash burn against its €20.5 million cash position to ensure it can fund its growth ambitions without resorting to potentially dilutive financing before the investments yield returns.
• The adoption rate and monetization of the new AI features serve as a key performance indicator for the company's ability to create a durable competitive advantage and justify the increased R&D expenditure.